Close Menu

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity said today that it has initiated coverage of liquid biopsy firm Guardant Health with a Buy rating and a price target of $90.

In a note to investors, analyst Mark Massaro said that he views Guardant as the leader in liquid biopsy cancer testing, adding that that stock gains so far have been justified and predicted that its shares will rise further. He estimated that the Guardant360 test is less than 5 percent penetrated in a $6 billion market for liquid biopsy therapy selection in advanced cancer patients.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.